Timothy Robinson
Analyst · Sidoti. Please go ahead
Thank you, Dan, and good afternoon everybody. In the first quarter, revenue was $70.6 million was in line with our expectations. Take Shape For Life accounted for approximately 82% of revenue. Medifast Direct accounted for 12.7%. Franchise Medifast Weight Control Centers accounted for 4.9%, and Medifast Wholesale accounted for 0.4% of net revenue. Revenue in Take Shape For Life increased 2.3% to $58 million from $56.7 million in the first quarter of the prior year. As Dan mentioned, there were approximately 13,000 active health coaches in the first quarter, compared to 12,600 in the same period last year and 12,500 in the fourth quarter of 2016. Average revenue per active earning health coach for the quarter decreased slightly to $4,463 as compared to $4,490 in first quarter of last year. Our Medifast Direct revenues decreased 18.3% to $8.9 million, as compared to $10.9 million in the first quarter of 2016. Total Medifast direct advertising in the quarter decreased 44% to $2.3 million from $4.1 million in the first quarter of 2016. This decrease is a result of our ongoing initiatives to optimize our advertising spend to acquire growing number of customers that support long-term profitable growth. Going forward, our strategy is to gradually shift our emphasis to an integrated business model driving online customers into our coaching model of gaining a higher lifetime value and minimizing any remaining conflict between our current business units. Revenue in the franchise Medifast Weight Control Centers decreased to 3.5 million from 4.2 million in the same period last year. The decrease in revenue is primarily driven by fewer franchise centers in operation during the period. We ended the quarter with 37 franchise centers in operation, across 19 reseller locations, compared to 58 centers at the end of the same period last year. Medifast Wholesale revenue, which is mostly comprised of revenues from healthcare providers decreased to $261,000, compared to $497,000 in the prior year period. Lower revenue was consistent with our previously communicated strategic decisions to reduce emphasis on the area of our business based on a significant number of healthcare providers in our Take Shape For Life coach community and our enforcement of our business partner compliance distribution requirements. Gross profit for the first quarter of 2017 decreased modestly to $52.9 million, compared to $53.2 million in the prior period. We were pleased to see our gross profit margin as a percentage of net revenue expand by 140 basis points, 74.9% versus 73.5% in the first quarter of 2016. The increase was driven primarily by price increases, and efficiencies in our supply chain operation. Selling, general and administrative expenses in the first quarter of 2017 were $44.3 million or 62.7% of revenues versus $46.9 million or 64.9% of revenues in the first quarter of last year. The first quarter of 2016 included a $1.2 million of restructuring costs and excluding these costs SG&A decreased 1$.4 million year-over-year. Adjusted selling, general, and administrative expenses as a percentage of net revenue decreased 60 basis points from 63.3% in the first quarter last year, compared to 62.7% for the first quarter of 2017. The decrease in SG&A was primarily a result of reduced and more effective advertising spend in Medifast brand. Sales and marketing expense decreased $1.4 million in the first quarter of 2017, as compared to the first quarter of 2016. Net income in the first quarter of 2017 was $6.1 million or $0.51 per share, based on approximately 12 million shares outstanding. First quarter of 2016 net income was $4.3 million or $0.36 per diluted share, based on approximately 11.9 million shares outstanding. Excluding $800,000 of restructuring cost, net of taxes, net income in the first quarter of 2016 would have been $5 million or $0.42 per diluted share. Our effective tax rate was 29.5%, compared to 33% in the first quarter of 2016 decreasing the effective tax rate was due to the change in accounting for taxes associated with share-based compensation. Our balance sheet remains very strong with shareholders equity of $99.2 million, and working capital of $80.5 million as of March 31, 2017. Cash, cash equivalents and investment securities as of March 31, 2017 increased $2.2 million to $79 million, compared to $76.8 million at December 31, 2016. We continue to have approximately 850,000 shares remaining in our repurchase authorization as of March 31, 2017. Our board of directors declared a $0.32 quarterly dividend during the quarter payable on May 9. Turning to our guidance. We expect second quarter revenue to be in the range of $72 million to $75 million, and earnings per diluted share to be in the range of $0.51 to $0.54 per diluted share. We are reiterating our 2017 full-year guidance. We expect full-year revenue to be in the range of $290 million to $300 million and full-year earnings per diluted share to be in the range of $2 and $2.10 per diluted share. Our fiscal year 2017 guidance assumes a 33% to 34% effective tax rate. That concludes our operational and financial review. We appreciate your interest in Medifast and Dan and I are now available to take your questions. Operator?